NAPSR News: Pfizer receives FDA Priority Review for breast cancer drug palbociclib

The United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for Pfizer's palbociclib. The NDA submitted requests approval of palbociclib, in combination with letrozole.



via Education - Latest News http://www.prlog.org/12382377-napsr-news-pfizer-receives-fda-priority-review-for-breast-cancer-drug-palbociclib.html